高瓴！首个“资深专业机构投资者”

Core Viewpoint - The recognition of Zhuhai Hillhouse as a qualified professional institutional investor marks a significant milestone for Tianomaibo's IPO process on the Sci-Tech Innovation Board, being the first company to be accepted under the new fifth listing standard [1][2]. Group 1: Company Overview - Tianomaibo Pharmaceutical Co., Ltd. has received acceptance for its IPO application on the Sci-Tech Innovation Board, making it the first company to be accepted under the newly restarted fifth listing standard [1]. - The company has a diverse base of institutional investors, with over 40 participating in its last four financing rounds, including notable shareholders such as Kangzhi Pharmaceutical and Gree [3]. Group 2: Institutional Investor Recognition - Zhuhai Hillhouse was recognized as a qualified professional institutional investor, having held a stake of 3.94% in Tianomaibo for over 24 months, meeting the new regulatory requirements [2]. - The new regulations stipulate that qualified institutional investors must hold at least 3% of the company's shares or invest no less than 500 million yuan prior to the IPO application [1][2]. Group 3: Investment Strategy and Market Impact - The introduction of the qualified professional institutional investor system aims to enhance the assessment of companies' technological attributes and commercial prospects, thereby reducing the risk of low-quality companies entering the market [3]. - The investment model is shifting from "Pre-IPO arbitrage" to a full-cycle accompaniment approach, which demands higher professional judgment capabilities from investment institutions [3].